Valuation: ADMA Biologics, Inc.

Market Cap 2.22B 1.92B 1.79B 1.64B 3.09B 211B 3.14B 21.02B 8.25B 106B 8.33B 8.14B 350B P/E 2026 *
12.2x
P/E 2027 * 9.71x
Enterprise Value 2.22B 1.92B 1.79B 1.64B 3.09B 211B 3.14B 21.02B 8.25B 106B 8.33B 8.14B 350B EV / Sales 2026 *
4.14x
EV / Sales 2027 * 3.17x
Free-Float
90.52%
Yield 2026 *
-
Yield 2027 * -
1 day-1.59%
1 week+17.02%
Current month+17.02%
1 month+6.80%
3 months+21.18%
6 months-39.52%
Current year-45.72%
1 week 8.66
Extreme 8.66
10.35
1 month 8.16
Extreme 8.165
10.35
Current year 7.21
Extreme 7.2101
18.95
1 year 7.21
Extreme 7.2101
20.46
3 years 3.06
Extreme 3.06
25.67
5 years 1.01
Extreme 1.01
25.67
10 years 1.01
Extreme 1.01
25.67
Manager TitleAgeSince
Chief Executive Officer 49 2011-09-30
Director of Finance/CFO 49 2026-02-25
Compliance Officer 39 2017-12-31
Director TitleAgeSince
Director/Board Member 78 2006-12-31
Chairman 62 2012-03-29
Director/Board Member 49 2006-12-31
Date Insider Type Main position Quantity % Market Cap.
7/24/26 Tax

Compliance Officer

-3,177 0.0014%
7/16/26 Free

Chief Financial Officer

221,493 0.0956%
2/26/26 Other

Chief Financial Officer

149,185 0.0627%
Change 5-day change 1-year change 3-year change Capi.($)
-1.59%+17.02%-40.07%+143.84% 2.22B
+1.59%+2.85%+39.32%-0.16% 78.32B
+2.77%+4.78%-0.98%+26.82% 51.1B
-0.84%+0.09%+20.92%+173.68% 49.18B
+1.72%+8.18%-49.03%-49.18% 44.71B
+0.80%+2.46%+59.13%-23.35% 30.72B
+1.84%+0.87%+53.80%+84.29% 24.44B
+9.86%+7.94%+126.53%-41.89% 23.62B
+3.22%+13.84%+8.84%+204.04% 21.05B
+1.66%-3.70%+66.13%+119.15% 16.61B
Average +2.10%+5.37%+28.46%+63.72% 34.2B
Weighted average by Cap. +2.04%+4.37%+26.85%+42.82%

Financials

2026 *2027 *
Net sales 535M 463M 432M 397M 746M 50.95B 758M 5.07B 1.99B 25.54B 2.01B 1.97B 84.43B 700M 606M 566M 519M 976M 66.65B 992M 6.64B 2.61B 33.41B 2.63B 2.57B 110B
Net income 191M 165M 155M 142M 267M 18.21B 271M 1.81B 712M 9.13B 718M 703M 30.17B 248M 214M 200M 183M 345M 23.57B 351M 2.35B 921M 11.81B 930M 910M 39.05B
Net Debt - -
Logo ADMA Biologics, Inc.
ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV (immune globulin intravenous, human-slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM (immune globulin intravenous, human) for the treatment of PI; and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.
Employees
644
Date Price Change Volume
26-08-07 US$9.900 -1.59% 3,305,414
26-08-06 US$10.06 +8.64% 5,616,059
26-08-05 US$9.260 +3.93% 3,800,478
26-08-04 US$8.910 +1.95% 2,820,376
26-08-03 US$8.740 +3.31% 2,572,849
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
9.900USD
Average target price
17.00USD
Spread / Average Target
+71.72%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ADMA Stock